# Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

> **NCT03665610** · — · COMPLETED · sponsor: **Celgene** · enrollment: 212 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ozanimod

## Key facts

- **NCT ID:** NCT03665610
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-10
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-01-10
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665610, "Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03665610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*